PEP-1-metallothionein-III protein ameliorates the oxidative stress-induced neuronal cell death and brain ischemic insults

Biochim Biophys Acta. 2012 Oct;1820(10):1647-55. doi: 10.1016/j.bbagen.2012.06.012. Epub 2012 Jun 26.

Abstract

Background: Oxidative stress is considered to be involved in a number of human diseases including ischemia. Metallothioneins (MT)-III can protect neuronal cells from the cytotoxicity of reactive oxygen species (ROS). However, MT-III proteins biological function is unclear in ischemia. Thus, we examined the protective effects of MT-III proteins on oxidative stress-induced neuronal cell death and brain ischemic insult.

Methods: A human MT-III gene was fused with a protein transduction domain, PEP-1 peptide, to construct a cell permeable PEP-1-MT-III protein. PEP-1-MT-III protein was purified using affinity chromatograph. Transduced PEP-1-MT-III proteins were detected by Western blotting and immunoflourescence. Cell viability and DNA fragmentation were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheyltetrazolium bromide (MTT) assay and terminal dexoynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, respectively. Brain ischemic injury was detected with immunohistochemistry.

Results: Purified PEP-1-MT-III proteins transduced into astrocytes in a time- and dose-dependent manner and protected against oxidative stress-induced cell death. Also, transduced PEP-1-MT-III proteins efficiently protected cells against DNA fragmentation. Furthermore, immunohistochemical analysis revealed that PEP-1-MT-III prevented neuronal cell death in the CA1 region of the hippocampus induced by transient forebrain ischemia. We demonstrated that transduced PEP-1-MT-III protein protects against oxidative stress induced cell death in vitro and in vivo.

General significance: Transduced PEP-1-MT-III protein has neuroprotective roles as an antioxidant in vitro and in vivo. PEP-1-MT-III protein is a potential therapeutic agent for various human brain diseases such as stroke, Alzheimer's disease, and Parkinson's disease.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Brain Ischemia / prevention & control
  • Cell Death / drug effects
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Cells, Cultured
  • Cysteamine / analogs & derivatives*
  • Cysteamine / chemistry
  • Cysteamine / pharmacology
  • Cysteamine / therapeutic use
  • Gerbillinae
  • Lipid Peroxidation / drug effects
  • Lipid Peroxidation / genetics
  • Metallothionein 3
  • Nerve Tissue Proteins / chemistry
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / pharmacology*
  • Nerve Tissue Proteins / therapeutic use
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / physiology
  • Oxidative Stress / drug effects*
  • Oxidative Stress / genetics
  • Peptides / chemistry
  • Peptides / genetics
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Rats
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology
  • Recombinant Fusion Proteins / therapeutic use
  • Transduction, Genetic / methods

Substances

  • Metallothionein 3
  • Nerve Tissue Proteins
  • Pep-1 peptide
  • Peptides
  • Recombinant Fusion Proteins
  • Cysteamine